Sign In
Buy ASND
$243.91
-7.16 (-2.85%)
At Close: Jul 31, 2026
Ascendis Pharma price target raised to $219 from $199 at Oppenheimer ASND
01:02pm, Monday, 20'th Apr 2020
Ascendis Pharma price target raised to $219 from $199 at Oppenheimer Oppenheimer ASND
Ascendis Pharma price target raised to $170 from $166 at Canaccord ASND
12:03pm, Monday, 20'th Apr 2020
Ascendis Pharma price target raised to $170 from $166 at Canaccord Canaccord ASND
Ascendis Pharma price target raised to $149 from $139 at Credit Suisse ASND
12:02pm, Monday, 20'th Apr 2020
Ascendis Pharma price target raised to $149 from $139 at Credit Suisse Credit Suisse ASND
Ascendis Pharma price target raised to $201 from $185 at Cantor Fitzgerald ASND
11:29am, Monday, 20'th Apr 2020
Ascendis Pharma price target raised to $201 from $185 at Cantor Fitzgerald Cantor Fitzgerald ASND
Ascendis Pharma (ASND) Received its Third Buy in a Row
11:24am, Monday, 20'th Apr 2020
After Merrill Lynch and Canaccord Genuity gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another Buy, this time from
Ascendis Pharma (ASND) Received its Third Buy in a Row
11:24am, Monday, 20'th Apr 2020
After Merrill Lynch and Canaccord Genuity gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another
Ascendis Pharma's TransCon PTH shows positive effect in adults with low parathyroid hormone
10:35am, Monday, 20'th Apr 2020
Ascendis Pharma A/S (NASDAQ:ASND) announces positive results from a Phase 2 clinical trial, PaTH Forward, evaluating TransCon PTH in adults with hypoparathyroidism (low levels for parathyroid hormone
Ascendis Pharma (ASND) Received its Third Buy in a Row
10:11am, Monday, 20'th Apr 2020
After Merrill Lynch and Oppenheimer gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another Buy, this time from
Ascendis Pharma (ASND) Received its Third Buy in a Row
10:11am, Monday, 20'th Apr 2020
After Merrill Lynch and Oppenheimer gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another Buy,
Ascendis Pharma A/S (NASDAQ:ASND) Rating Increased to Buy at BidaskClub
09:42am, Monday, 20'th Apr 2020
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Monday, BidAskClub reports. A number of other bro
Ascendis Pharma price target raised to $171 from $146 at Stifel ASND
09:31am, Monday, 20'th Apr 2020
Ascendis Pharma price target raised to $171 from $146 at Stifel Stifel ASND
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced positive top-line results from the four-week
– PaTH Forward Trial met key objectives and showed that TransCon PTH eliminated standard of care in 82 percent of subjects within four weeks – –...
Ascendis Pharma announces top-line data from fixed dose portion of PaTH Forward ASND
09:49am, Sunday, 19'th Apr 2020
Ascendis Pharma announces top-line data from fixed dose portion of PaTH Forward ASND
Edited Transcript of ASND earnings conference call or presentation 1-Apr-20 8:30pm GMT
01:40am, Friday, 17'th Apr 2020
Q4 2019 Ascendis Pharma A/S Earnings Call
